gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Predictive factors for patients with small cell lung carcinoma (SCLC) undergoing first-line ACE chemotherapy – results after long term follow-up of median 7.5 years

Meeting Abstract

  • corresponding author presenting/speaker Wolfgang M. Brueckl - Universitätsklinikum, Erlangen, Deutschland
  • Larissa Herbst - Universitätsklinikum, Erlangen
  • Annette Lechler - Universitätsklinikum, Erlangen
  • Sabine Zirlik - Universitätsklinikum, Erlangen
  • Florian Fuchs - Universitätsklinikum, Erlangen
  • Thomas Brunner - Universitätsklinikum, Erlangen
  • Peter Klein - Universitätsklinikum, Erlangen
  • Thomas Papadopoulos - Universitätsklinikum, Erlangen
  • Werner Hohenberger - Universitätsklinikum, Erlangen
  • Eckhart G. Hahn - Universitätsklinikum, Erlangen
  • Gunther H. Wiest - Universitätsklinikum, Erlangen

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO158

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk268.shtml

Published: March 20, 2006

© 2006 Brueckl et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Background: Despite a high chemosensitivity, small cell lung carcinoma (SCLC) remains associated with a poor long term outcome. The purpose of this retrospective study was to identify predictive factors for overall survival of patients with SCLC undergoing first-line chemotherapy with a well established combination consisting of -Adriamycin, Cyclophosphamide and Etoposide (ACE).

Methods: Between 1989 and 2004 a total of 166 patients with SCLC were diagnosed and treated at one institution. Of those, n=134 patients were treated with first-line with chemotherapy; n=106 received ACE. The median follow-up was 7.5 years.

Results: Median overall survival (mOS) of patients receiving ACE was 9,36 months with median survival rates of 31, 8% and 3% after 1, 2 and 5 years, respectively. The following parameters were associated with significant differences in median overall survival (mOS) by univariate analysis: limited disease vs extended disease, p=0.022; ECOG-PS 0, I, II, III, p<0.001; White blood count (WBC) <10/nl vs>10/nl, p<0.001; Lactate dehydrogenase (LDH) <250 U/l vs >250 U/l, p=0.022. Gender, age and dose reduction during chemotherapy were not associated with differences in mOS. Using multivariate cox-regression analysis ECOG-PS (p=0.008) and WBC (p=0.022) were independent predictive factors for mOS. Three groups of outcome could be built with good, intermediate and poor prognosis resulting in mOS rates of 15.8, 6.87 and 3.35 months, respectively (p<0.0001).

Conclusions: (1) Survival rates of patients receiving ACE chemotherapy was similar as reported in the literature. (2) ECOG-PS and WBC, were independent predictive factors for outcome after long term follow-up. Patients with the poor prediction profile (ECOG-PS >0 and WBC >10/nl) will probably not benefit from ACE chemotherapy. However, this hypothesis has to be tested prospectively.

Figure 1 [Fig. 1]